Upon target RNA recognition, type III CRISPR-Cas systems produce cyclic oligoadenylate second messengers to activate downstream effectors including Csm6-family ribonucleases via their CARF domains. Here we show that Enteroccocus italicus Csm6 (EiCsm6) degrades its cognate cyclic hexa-AMP (cA6) activator and report the crystal structure of EiCsm6 bound to a cA6 mimic. The structure, combined with biochemical and in vivo functional assays, reveal how cA6 recognition by the CARF domain activates the Csm6 HEPN domains for collateral RNA degradation, and how CARF domain-mediated cA6 cleavage provides an intrinsic off-switch to limit Csm6 activity in the absence of ring nucleases. These mechanisms facilitate rapid invader clearance and ensure termination of CRISPR interference to limit selftoxicity.
Introduction
CRISPR-Cas systems are defense mechanisms present in many bacteria and most archaea that provide RNA-guided immunity against genetic invaders such as bacteriophages and plasmids 1, 2 . CRISPR-Cas systems can be divided in two classes and six types based on their composition and the presence of specific CRISPR-associated (cas) genes. Type III systems are characterized by the presence of the signature protein Cas10 in their multisubunit CRISPR RNA (crRNA)-guided effector complexes, termed Csm complexes in subtypes III-A and III-D, and Cmr complexes in subtypes III-B and III-C 3 . These complexes directly recognize invader-derived RNA transcripts and harbor two target-dependent nuclease activities, whereby Cas10 subunit (also known as Csm1 or Cmr2) is allosterically activated to degrade single-stranded DNA in a sequence non-specific manner using its HD domain, while the Csm3/Cmr4 subunits cleave the bound RNA in a sequence specific manner [4] [5] [6] [7] [8] [9] [10] .
Additionally, target RNA binding activates the Palm domain of the Cas10 subunit of the Csm/Cmr complexes to convert ATP into cyclic oligoadenylate (cOA) second messengers of various sizes, which in turn allosterically activate CRISPR-associated Rossman-fold (CARF) domain-containing effector proteins including Csm6/Csx1 ribonucleases [11] [12] [13] [14] . The type III CRISPR-Cas systems found in different organisms have been shown to produce different cOA species; whereas Streptococcus thermophilus and Enterococcus italicus generate cyclic hexa-AMP (cA6), Thermus thermophilus, Sulfolobus islandicus or Sulfolobus solfataricus produce cyclic tetra-AMP (cA4) [11] [12] [13] [14] . Upon activation, the RNase activity of Csm6/Csx1 enzymes, catalyzed by their 'higher eukaryotes and prokaryotes nucleotide binding' (HEPN) domains, provides an auxiliary interference mechanism to facilitate invader clearance and may induce dormancy or cell death. Previous studies demonstrated its requirement for efficient in vivo immunity, specifically when targeting late genes 13, [15] [16] [17] . In some type III CRISPR-Cas systems, cOA signaling is terminated by standalone CARF domain-containing ring nucleases, proteins able to degrade cA4 to yield linear adenosine tetra-and dinucleotides 18 . Furthermore, recent studies have shown that some Csm6-family enzymes can also intrinsically catalyze cOA degradation and thus possess a self-inactivation mechanism 19, 20 .
Although Csm6/Csx1 proteins that are activated by cA4 have been recently characterized 20, 21 , the molecular mechanisms of cA6-dependent Csm6 RNases remain elusive. In this study, we show that the type III CRISPR-associated RNase Csm6 from Enterococcus italicus (EiCsm6), which is activated by cA6, possesses an intrinsic cA6 degradation activity mediated by its CARF domain. Our crystal structure of EiCsm6 in complex with a non-degradable cA6 mimic, together with supporting biochemical and functional studies, reveal the mechanisms of cA6 sensing and degradation, as well as cA6mediated allosteric activation of EiCsm6. These results provide a mechanistic framework for understanding the function of CARF domain-containing effector RNase in the context of CRISPR-Cas immunity.
Results

The CARF domain of Csm6 is a ring nuclease
We previously showed that the ribonuclease Csm6 associated with the type III CRISPR-Cas system from Enterococcus italicus is activated by cyclic hexa-AMP (cyclic hexa-adenylate, cA6) 22 . To test whether EiCsm6 is capable of degrading cA6, we analyzed reaction mixtures containing cA6 and wild-type (WT) EiCsm6 using liquid-chromatography-mass spectrometry (LC-MS), revealing that cA6 was efficiently degraded to yield a mixture of products, including a species with a m/z ratio of 986.1, matching that of linear tri-AMP carrying a 2',3'-cyclic phosphate group (Supplementary Figure 1) . cA6 was also efficiently degraded in the presence of RNase-deficient Csm6 containing a point mutation in the HEPN active site (H377A), excluding the possibility that the degradation is catalyzed solely by the HEPN domain ( Supplementary Figure 1 ). Corroborating these results, a cA6 sample pre-incubated in the presence of WT EiCsm6 protein was almost inactive in stimulating the RNase activity of WT EiCsm6 in a fluorogenic ribonuclease activity assay, indicative of cA6 degradation ( Supplementary Figure 2a,b) . Preincubation of cA6 with EiCsm6 containing inactivating mutations in the HEPN domain (R372A/N373A/H377A, herein referred to as dHEPN) resulted in partial degradation of cA6 and reduced activation of WT EiCsm6, as did pre-incubation with with EiCsm6 containing a mutation (T114A) in the conserved CARF domain motif. In contrast, preincubation with EiCsm6 containing mutations both in the HEPN RNase active site and in the CARF domain did not result in cA6 degradation (Supplementary Figure 2b) . Together, these experiments indicate that although the RNase activity of the HEPN domain contributes to cA6 degradation, the CARF domain of EiCsm6 is intrinsically capable of catalyzing cA6 degradation.
Crystal structure of Csm6 bound to cA6 mimic
The catalytic mechanism of cOA degradation by ring nucleases proceeds through a nucleophilic attack of the ribose 2'-hydroxyl to generate a 2',3'-cyclic phosphate product 19 .
Consistent with this, 2',2'',2''',2'''',2''''',2''''''-hexa-F-c-hexa-dAMP (cFA6), a cA6 mimic containing 2'-fluoro modifications in all positions, was resistant to degradation yet still capable of allosterically activating EiCsm6, albeit more weakly than cA6 (Supplementary Figure 3a- c). The half-maximal concentration (EC50) of cFA6 was determined to be 170 nM, approximately 50-fold higher than that of cA6 11 , likely due to weaker binding resulting from the 2'-fluoro modifications (Supplementary Figure 3d) .
To gain structural insights into the mechanism of cA6 binding, we co-crystallized EiCsm6 with cFA6 and determined the structure of the complex at a resolution of 2.4 Å (Supplementary Table 1 ). The structure reveals that EiCsm6 adopts the canonical homodimeric architecture of Csm6/Csx1 enzymes, with extensive dimerization interfaces between the CARF and HEPN domains. A single molecule of cFA6 is bound within a conserved pocket spanning the dimer interface of the CARF domains ( Fig. 1, Supplementary Figure 4a 
cA6 sensing by the Csm6 CARF domain
The EiCsm6-cFA6 structure reveals that the ligand is recognized by an extensive network of ionic and hydrogen bonding interactions with both the ribose-phosphate backbone and the adenine bases ( Supplementary Figure 4b, Supplementary Figure 6 ). The bases of nucleotides A1/A4 are inserted into a deep pocket and are recognized via hydrogen-bonding interactions with the side chain of Arg173 and the backbone carbonyl of Asp19, while A2/A5 and A3/A6 interact with the side chains of Glu80 and Thr39/Ser41, respectively ( Fig. 2a,b) . In turn, Gln116 forms a hydrogen bond with the phosphodiester group connecting A2/A5 and A3/A6 ( Fig. 2c) . Alanine substitution of a subset of conserved residues involved in cA6 binding, including Asn10, Thr114 and Gln116 (Supplementary Figure 6) , resulted in the reduction or near-complete loss of cA6-dependent RNase activity, confirming the importance of these residues for cA6 sensing (Fig. 2d) .
In previous studies, we showed that the RNase activity of Csm6 in vivo depends on its allosteric activation by cyclic oligoadenylates and demonstrated the compatibility between EiCsm6 and the Staphylococcus epidermidis Type III Cas10-Csm complex 22 . To validate our structural insights into cA6 sensing, we tested the in vivo activity of wild-type and CARF domain mutant EiCsm6 proteins when co-expressed with the S. epidermidis type III CRISPR-Cas system lacking DNase activity in the HD domain of the Cas10 subunit (dHD) and an inducible RNA target. Target-induced activation of WT EiCsm6 triggered growth arrest due to its collateral RNase activity, which was dependent on the presence of a targeting spacer in the CRISPR array, as shown previously for S. epidermidis Csm6 17 . In contrast, EiCsm6 mutants in which specific residues involved in cA6 sensing were substituted with alanine either did not cause growth arrest or impeded growth only weakly, thus validating the importance of the CARF domain residues for cA6 sensing and Csm6 activation in vivo ( Fig.   2e ).
Mechanism of autocatalytic cA6 degradation
The EiCsm6-cFA6 structure provides insights into the mechanism underpinning cA6 degradation. As a consequence of the C2'-endo ribose pucker in A6/A3 and the positioning of A1/A4 in its binding pocket, the A6-A1 (and A3-A4) dinucleotide is forced into a conformation favoring an in-line nucleophilic attack of the A6/A3 2'-hydroxyl group onto the downstream scissile phosphodiester group to form a 2',3'-cyclic phosphate trinucleotide product ( Fig. 3a) .
Whereas the 2'-fluoro group of A6/A3 (and, presumably, the 2'-hydroxyl in cA6) is in hydrogen-bonding contact with the backbone amide group of Asn10, the scissile phosphodiester group is stabilized by hydrogen-bonding interactions with the backbone amide group and the side chain of Thr11. Thus, cA6 degradation by EiCsm6 seems to be mediated primarily by steric factors that force the ligand to adopt a conformation compatible with in-line nucleophilic substitution and does not involve deprotonation of the attacking nucleophile or protonation of the leaving group by acid-base catalysis, as postulated for ring nucleases and other Csm6/Csx1 enzymes in previous studies [18] [19] [20] . To verify the functional role of Thr11 in cA6 degradation, we compared the cA6-dependent RNase activities of WT and T11A EiCsm6 proteins. The T11A EiCsm6 protein retained the ability to be allosterically activated by cA6 in vitro ( Fig. 2d) , although the mutation caused only a weak growth arrest phenotype in vivo ( Fig. 2e) , presumably because the cA6 levels generated by the Cas10-Csm complex upon target induction were insufficient to activate T11A EiCsm6 due to partially compromised cA6 binding. The T11A EiCsm6 protein was impaired in cA6 degradation, as indicated by a pre-incubation experiment (Supplementary Figure 7a ) and confirmed by LC- Figure 7b) . Additionally, the T11A EiCsm6 protein displayed sustained in vitro RNase activity in the presence of 500 nM cA6, as compared to WT Csm6, further indicating that it is deficient in cA6 degradation ( Fig. 3b) . Collectively, these results suggest that cA6 degradation by the CARF domain of EiCsm6 intrinsically limits the sequence non-specific RNase activity of the enzyme's HEPN domain, which might prevent self-toxicity and contribute to the termination of the CRISPR immune response in vivo. To test this hypothesis, we examined the effect of expressing WT or T11A EiCsm6 in the presence of a S. epidermidis Cas10-Csm complex that was deficient in target RNA degradation due to an inactivating mutation in the Csm3 subunit (D32A, dCsm3), which results in sustained production of cA6. At low levels of target induction, WT EiCsm6 was unable to cause growth arrest ( Fig. 3c) . In contrast, the T11A EiCsm6 mutation resulted in a strong growth inhibition phenotype, indicating that the loss of ring nuclease activity in the CARF domain results in the hyperactivation of EiCsm6.
MS analysis (Supplementary
cA6-dependent activation mechanism of Csm6
Owing to the homodimeric architecture of Csm6 enzymes, their HEPN nuclease domains form a composite RNase active site at the domain interface 23 . In the EiCsm6-cFA6 structure, the site is occupied by a sulfate ion originating from the crystallization solution, acting as a mimic of the scissile phosphate in an RNA substrate (Fig. 4a) . The anion is contacted by saltbridge interactions with Arg372 and flanked by a pair of His377 side chains, which are part of the R-X4-H HEPN domain motif and predicted to elicit acid-base catalysis based on homology with other HEPN-domain RNases 24 (Supplementary Figure 8) . The disposition of the active site residues is similar as in the activated-state structures of both RNase L and cA4-recognizing Csm6/Csx1 RNases ToCsm6 and SisCsx1 20, 21, 25, 26 , indicating that the HEPN domains adopt the activated conformation in the EiCsm6-cFA6 complex. Some Csm6 enzymes display basal HEPN-dependent RNase activity in the absence of cOA ligands 15, 23, 27 , suggesting that their HEPN domains sample a conformational equilibrium between activated and inactive states. This is supported by the observation that the conformations of apo-ToCsm6 and apo-SisCsx1 are nearly identical to their respective cA4-bound structures 20, 21 , suggesting that they may represent the activated state. Based on these considerations, an allosteric activation model for EiCsm6 can be envisioned (Fig. 4b) .
In the absence of cA6, EiCsm6 exists in a dynamic conformational equilibrium between inactive and activated forms, with the inactive form(s) being predominant. The HEPN domain active center and the CARF domain cA6 binding site are allosterically coupled. cA6 binding to the CARF domain interface preferentially stabilizes the activated form, in which the HEPN domain histidine residues are properly oriented to catalyze RNA degradation by an acid-base mechanism. While bound to cA6, the CARF domains act as a ring nucleases whose slow activity converts cA6 into two molecules of 2',3'-cyclic phosphate-terminated tri-AMP and triggers product dissociation. This leads to termination of the HEPN domain RNase activity by destabilization of the activated conformation. The biological activity of Csm6 enzymes is thus controlled by the interplay of the HEPN domain RNase activity and the slow, cis-acting ring nuclease activity of the CARF domain.
Discussion
In sum, the structural and biochemical studies presented in this study provide insights into the molecular mechanisms responsible for cA6 sensing, allosteric activation, and autocatalytic inactivation in Csm6 enzymes. We previously demonstrated the allosteric activation of EiCsm6 by cA6 generated by the Palm domain of Cas10 upon RNA target recognition 22 . We (Supplementary Figure 6) . Notably, the cA6 degradation mechanism of EiCsm6 does not involve acid-base catalysis, contrary to mechanisms postulated for other Csm6/Csx1 enzymes and ring nucleases [18] [19] [20] . Finally, the superposition of the EiCsm6 HEPN domains to other HEPN-domain nucleases indicates that EiCsm6 bound to cFA6 is stabilized in an activated state, pointing to a mechanism for cOA-dependent allosteric activation of Csm6/Csx1 proteins relying on conformational selection.
In the context of CRISPR-Cas immunity, self-degradation of cOA by Csm6/Csx1family RNases likely provides a mechanism for temporal control of their collateral RNase activity. Together with the target-directed RNase activity of the Cas10 effector complex, which leads to target cleavage and cessation of cOA production, this ensures termination of the antiviral response upon invader clearance. In some type III CRISPR-Cas systems, the ring nuclease activity may limit the self-toxicity of Csm6 enzymes, particularly in systems that do not possess standalone ring nucleases. Consistent with this, we demonstrate that impairment of the CARF domain ring nuclease activity in EiCsm6 results in its hyperactivation and CRISPR self-toxicity. Finally, the widespread occurrence of type III CRISPR-Cas systems, as well as the recently discovered bacterial cGAS/DncV-like nucleotidyltransferase (CD-NT) enzymes that synthesize diverse cyclic di-and trinucleotides 28 , combined with the diversity of their downstream effectors 29, 30 , suggests that cyclic oligonucleotide-dependent signaling is an important aspect of prokaryotic genome defense systems and awaits further mechanistic studies of their regulation.
Methods
Protein expression and purification
The gene sequence of EiCsm6 was amplified from genomic DNA (Enterococcus italicus DSM-15952) by PCR and cloned into a 1B vector (Addgene 29653) using ligationindependent cloning resulting in constructs carrying an N-terminal hexahistidine tag followed by a Tobacco Etch Virus (TEV) protease cleavage site. Point mutations were introduced by inverse PCR and verified by DNA sequencing. EiCsm6 and its mutants were purified similarly as described before 11 
X-ray crystallography
Ribonuclease activity assays
The RNase activity of EiCsm6 and its activation was assayed using a fluorogenic substrate similarly as described before 22 For the pre-incubation assay of cA6 with EiCsm6 or its mutants ( Supplementary   Figures 2 and 7) , 100 nM of protein were incubated with 1 µM of cA6 with for 60 min at 37 °C in a total volume of 100 µl. The reaction was stopped by incubating the sample at 95 °C for 5 min and denatured EiCsm6 was removed by centrifugation (16000 xg for 5 minutes).
Subsequently, 2 µl of the reaction supernatant (or 20 nM of cA6 as positive control) were added to 2 nM of WT EiCsm6 for activity assay using RNaseAlert as described above. The experiments were done in parallel and the results are presented in two figures for clarity, with the same set of controls. For the pre-incubation assay with cA6 or cFA6 ( Supplementary   Figure 3 ), 1 µM of WT EiCsm6 was incubated with 10 µM of cA6 or cFA6 for 60 min at 37 °C in a total volume of 100 µl. After inactivation, 1 µl of the reaction supernatant (or 0.1 µM cA6 as positive control) were used with 20 nM WT EiCsm6 in the RNaseAlert activity assay.
Csm6 toxicity growth curves
Growth curves from EiCsm6 interference against pTarget was performed as previously described 17 . Briefly, overnight cultures containing plasmids pTarget and pCRISPR (pJTR366, pJTR367, pJTR368, pJTR369, pJTR417, pJTR422, or pGG-BsaI-R for the dHD loss-of function experiments, and pJTR413, pJTR415, or pGG-BsaI-R for the gain-of-function experiments) were diluted and normalised for optical density (OD) measured at a wavelength of 600 nm. Cells were then seeded in a 96 well plate and target transcription was induced with anhydrous tetracycline (12.5 ng ml -1 for the experiment shown in Fig. 2e , or 5 ng ml -1 for the experiment shown in Fig. 3c ). OD readings were then obtained every 10 minutes with a microplate reader (TECAN Infinite 200 PRO).
Molecular cloning for in vivo assays
pJTR366 was generated by amplifying pJTR109 with JTR632 and JTR633, and pJTR179 with JTR915 and JTR918), and combining the PCR products by Gibson assembly 39 . pJTR367 was generated by amplifying pJTR109 with JTR632 and JTR633, and pJTR181 with JTR915 and JTR918), and combining the PCR products by Gibson assembly. pJTR368 was generated by first making pJTR355 (by amplifying pJTR179 with JTR223 and JTR924, and with JTR921 and JTR224, and combining the PCR products by Gibson assembly), and them amplifying pJTR109 with JTR632 and JTR633 and pJTR355 with JTR915 and JTR918, and combining the PCR products by Gibson assembly. pJTR369 was generated by first making pJTR356 (by amplifying pJTR179 with JTR223 and JTR924, and by JTR921 and JTR224, and combining the PCR products by Gibson assembly), and amplifying pJTR109 with JTR632 and JTR633, and pJTR356 with JTR915 and JTR918, and combining the PCR products by Gibson assembly. pJTR417 was generated by amplifying pJTR366 with W852 and JTR967, and with W614 and JTR966, and combining the PCR products by Gibson assembly. pJTR422 was generated by amplifying pJTR366 with W852 and JTR969, and with W614 and JTR968, and combining the PCR products by Gibson assembly. pJTR413 was generated by amplifying pJTR360 with W852 and PS466, and with W614 and PS465, and combining the PCR products by Gibson assembly. pJTR415 was generated by amplifying pJTR366 with W852 and PS466, and with W614 and PS465, and combining the PCR products by Gibson assembly. pGG-BsaI-R was described previously 40 . The plasmids and primers used for in vivo assays are described in Supplementary Tables 2 and 3 respectively.
EC50 analysis for cFA6
RNase activities were measured for reactions containing 5 nM of EiCsm6 supplemented with the indicated cFA6 concentrations. Initial velocities were calculated during the first 100 s and were plotted against cFA6 concentrations in GraphPad and fitted by using a nonlinear regression analysis using the log(dose)-versus-response relationship, assuming a variable Hill coefficient.
LC-MS analysis
The degradation of cA6 or cFA6 was assayed by incubating equimolar amounts (final concentration of 25 µM) with WT EiCsm6 or the H377A mutant at 37 °C for 1 hour in a total volume of 40 µl for Supplementary Figures 1 and 3 . For Supplementary Figure 6a Elution parameters are provided in Supplementary Table 4 .
cFA6 synthesis
All reagents and solvents for chemical operations were of analytical grade or the highestpurity grade available from commercial suppliers. Solvents for chromatographic operations were specified as analytical grade, HPLC-grade, or gradient HPLC-grade. YMC*Gel SIL (6 nm, S-75 µm) was used for preparative flash chromatography and TLC was performed with Merck 60 F254 silica gel plates. All chromatographic operations were performed at ambient temperature. Evaporation of solvents was accomplished by rotary evaporation in vacuo either with membrane pump vacuum or oil pump high vacuum with water bath temperatures not exceeding 30-33°C.
UV-spectra were recorded on a JASCO V-650 spectrometer in phosphate buffered aqueous solution (pH 7). Mass spectra were generated with a Bruker Esquire LC 6000 spectrometer in the electrospray ionization mass spectrometry (ESI-MS) mode with 50% water/49.5% methanol/0.5% NH3 (pH 9-10) as matrix. Nuclear magnetic resonance (NMR) spectra were recorded with a 400 MHz Bruker Avance III HD and chemical shifts are expressed in parts per million (ppm). Chemical shifts were referenced to the DMSO solvent signal, 2.50 ppm for 1 H.
85% phosphoric acid was used as external standard for 31 41 with the following modifications: After initial phosphonate preparation and after each coupling step with 1.4 eq. 5'-DMTr-2'-F-3'-CEP-N 6 -Bz-adenosine and 2 eq. 5-ethylthiotetrazole as coupling reagent the raw material was purified by preparative flash chromatography on silica gel using a step-gradient of methanol in dichloromethane. The final cyclization step and the release of protection groups was performed according to a standard protocol 41 , leading to the raw product cFA6 after evaporation of solvents. 100 mL water was added and the resulting suspension was placed in an ultrasonic bath at room temperature for 15 minutes. Afterwards, additional 100 mL water was added followed by 3 extraction cycles with 200 ml chloroform each. The combined organic phases were extracted with 300 ml water and the combined product-containing aqueous phase was filtered with a 0.45 µm regenerated cellulose (RC) filter and concentrated under reduced pressure. The complex reaction mixture was initially purified by repeated preparative reversed phase medium pressure liquid chromatography (MPLC). The product solution was applied to a Merck LiChroprep®RP-18 column (15 -25 µm; 450 x 50 mm) previously equilibrated with 100 mM triethylammonium formate (TEAF, pH 6.8) in water. Elution was performed with a step-gradient of 3%, 4%, 6%, 
